{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-102222","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.600193+00:00","generated_at":"2026-05-17T02:19:43.834825+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M","bullets":["Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.","Omnibus equity plan share reserve raised from 470,000 to 1,400,000 shares, plus automatic annual increase.","All four director nominees re-elected; ratification of Salberg & Company as auditor approved.","Reverse split proposal received 3,896,499 for vs 1,253,332 against; plan amendment got 1,343,678 for vs 514,675 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-102222","json":"https://secwatch.observer/filing/0001213900-25-102222.json","markdown":"https://secwatch.observer/filing/0001213900-25-102222.md","text":"https://secwatch.observer/filing/0001213900-25-102222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/0001213900-25-102222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/ea0262461-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:19:43.834825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}